Pegaspargase preferred option in acute lymphoblastic leukaemia

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Access options

    Buy single article

    Instant unlimited access to the full article PDF.

    US$ 49.95

    Price includes VAT for USA

    Subscribe to journal

    Immediate online access to all issues from 2019. Subscription will auto renew annually.

    US$ 214

    This is the net price. Taxes to be calculated in checkout.


    1. 1.

      The study was sponsored by Baxalta, a member of the Takeda group of companies.


    1. Hu X, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review : 29 Dec 2019. Available from: URL:

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Pegaspargase preferred option in acute lymphoblastic leukaemia. PharmacoEcon Outcomes News 844, 30 (2020).

    Download citation